MDCX_OUT_1 [2025-04-03 14:16:10 -0400] 2728 Bytes | 759 tokens | Cum: 759 tkns (9.49% of 8k)
==========================================================================

Listen up, partner—it's 2:16:07 PM on Thu Apr 03, 2025 -0400, and I’m revved up about Medicus Pharma (MDCX), climbing from 3.4 to 3.8982. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Medicus Pharma (MDCX)
IPO: 2023-11-22 (1 Year Ago)
Market Cap: $49,835,986
Shares Outstanding: 13,420,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

Here's the first list of news for Medicus Pharma:

C1 - Mar-10-25 04:05PM - Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
C2 - Mar-06-25 08:30PM - Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
C3 - Mar-06-25 08:30PM 07:30AM - Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
C4 - Feb-27-25 07:30AM - Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
C5 - Feb-14-25 07:30AM - Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
C6 - Feb-11-25 07:41AM - Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
C7 - Dec-12-24 07:30AM - Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
C8 - Dec-02-24 07:30AM - Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Medicus Pharma (MDCX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

MDCX_OUT_3 [2025-04-03 14:16:14 -0400] 1099 Bytes | 331 tokens | Cum: 1092 tkns (13.65% of 8k)
==========================================================================

Showing C3 (chunk 1 of 11): C3:
**Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)**
Date: Mar-06-25 08:30PM 07:30AM
Source: (Newsfile)
URL: https://www.newsfilecorp.com/release/243509/Medicus-Pharma-Ltd-Announces-Positively-Trending-Interim-Analysis-for-SKNJCT003-Phase-2-Clinical-Study-to-NonInvasively-Treat-Basal-Cell-Carcinoma-of-the-Skin-BCC

We use cookies to analyze user behavior in order to constantly improve the website for you.Learn more.

Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).

The SKNJCT-003 clinical study is currently underway in nine (9) c

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MDCX_OUT_5 [2025-04-03 14:16:15 -0400] 918 Bytes | 263 tokens | Cum: 1414 tkns (17.68% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-21T12:15:00Z - Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025...
A2 - 2025-03-10T20:15:57Z - Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering...
A3 - 2025-03-10T20:08:22Z - Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering...
A4 - 2025-03-08T12:40:00Z - Medicus Pharma CEO discusses latest skin cancer trial results - ICYMI...
A5 - 2025-03-07T15:00:00Z - Small cap wrap: G Mining Ventures, Wedgemount Resources, Medicus Pharma......

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MDCX_OUT_7 [2025-04-03 14:16:16 -0400] 1099 Bytes | 264 tokens | Cum: 1680 tkns (21.00% of 8k)
==========================================================================

Showing A1 (chunk 1 of 15): A1:
**Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025**Date: 2025-03-21Source: {'uri': 'proactiveinvestors.com', 'dataType': 'news', 'title': 'Proactiveinvestors NA'}URL: https://www.proactiveinvestors.com/companies/news/1068317/healthcare-investment-strategies-reshaped-by-inflation-interest-rates-and-m-a-in-2025-1068317.htmlFrom potential changes in government healthcare policies to persistent inflationary pressures and evolving investment strategies, the US healthcare sector is facing a convergence of economic, regulatory, and political forces that could reshape the industry's trajectory for years to come.

As the industry emerges from the lingering effects of the COVID-19 pandemic, healthcare companies must adapt to new cost structures, shifting reimbursement models, and an increasingly competitive landscape.

Analysts at UBS have assessed the st

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MDCX_OUT_9 [2025-04-03 14:16:17 -0400] 1099 Bytes | 222 tokens | Cum: 1904 tkns (23.80% of 8k)
==========================================================================

Showing A1 (chunk 2 of 15): ate of the healthcare market across key subsectors, outlining the factors that could drive -- or hinder -- growth.

A major concern for investors is the potential impact of regulatory shifts under the Trump administration, particularly regarding the Food and Drug Administration (FDA) and Medicare. Discussions around Medicaid funding, site-neutral payments, and pharmaceutical pricing reforms remain central to the policy debate, while proposed tariffs on pharmaceuticals and medical supplies add another layer of complexity to the investment outlook.

At the same time, innovation remains a core theme across the industry. Advances in biotechnology, medical devices, and diagnostic tools continue to unlock new treatment possibilities, providing opportunities for companies positioned at the forefront of research and development. However, macroeconomic headwinds, such as inflation and rising inte

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MDCX_OUT_11 [2025-04-03 14:16:17 -0400] 517 Bytes | 159 tokens | Cum: 2065 tkns (25.81% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-24T15:00:00Z - Cartoning Machines Market Size to Approach USD 13.58 Bn by 2034
B2 - 2024-12-12T12:30:00Z - Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MDCX_OUT_13 [2025-04-03 14:16:21 -0400] 665 Bytes | 198 tokens | Cum: 2265 tkns (28.31% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Cartoning Machines Market Size to Approach USD 13.58 Bn by 2034**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/24/3001722/0/en/Cartoning-Machines-Market-Size-to-Approach-USD-13-58-Bn-by-2034.htmlThe cartoning machines market is expected to grow from $8.30 billion in 2024 to $13.58 billion by 2034, driven by the increasing adoption of automation and sustainable packaging solutions across various industries.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MDCX_OUT_15 [2025-04-03 14:16:22 -0400] 1110 Bytes | 293 tokens | Cum: 2644 tkns (33.05% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-28 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

This discussion contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncert...

S2 - 2025-03-11 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 6, 2025, Medicus Pharma Ltd. ("Medicus" or the "Company") entered into a Placement Agency Agrmt (the "Placement Agency Agrmt") with Maxim Group LLC, as representative of the placement agents named therein (...

S3 - 2025-02-11 8-K Item 1.01. Entry into a Material Definitive Agrmt.

Standby Equity Purchase Agrmt

On February 10, 2025, Medicus Pharma Ltd. ("Medicus" or the "Company") entered into a Standby Equity Purchase Agrmt (the "SEPA") with YA II PN, Ltd. ("Yorkville"). Pursuant to the SEP...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MDCX_OUT_17 [2025-04-03 14:16:23 -0400] 1098 Bytes | 236 tokens | Cum: 2882 tkns (36.02% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

This discussion contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that impact our business. In particular, we encourage you to review the risks and uncertainties described in "Risk Factors" in Part I, Item 1A in this Annual Report on Form 10-K. These risks and uncertainties could cause actual results to differ materially from those projected or implied by our forward-looking statements contained in this report. These forward-looking statements are made as of the date of this annual report, and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. All amounts are expressed in United States dollars un

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MDCX_OUT_19 [2025-04-03 14:16:24 -0400] 1098 Bytes | 235 tokens | Cum: 3119 tkns (38.99% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): less otherwise stated.

Company Overview

The Company is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials. Utilizing a thesis driven collaborative process, the Company attempts to acquire and advance clinical stage assets through clinical development and commercialization. The Company looks into opportunities across all therapeutics areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring to expand its drug development pipeline through qualified and accretive acquisitions and partnerships.

The Company has two wholly owned subsidiaries, Medicus Pharma Inc., a company incorporated in the state of Delaware on October 12, 2023, and SkinJect, Inc. ("SkinJect").

SkinJect is focused on the development of a novel

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MDCX_OUT_21 [2025-04-03 14:16:36 -0400] 4116 Bytes | 1159 tokens | Cum: 4280 tkns (53.50% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+----------------------+------------------------+-----------------------+
| Volume: 73,966 | Perf Month: 25.74% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+----------------------+------------------------+-----------------------+
| Avg Volume: 51.75K | Perf Quarter: 56.80% | Short Float: 2.79% | ROE: -525.44% |
+--------------------+----------------------+------------------------+-----------------------+
| Rel Volume: 2.02 | Index: - | Short Ratio: 1.44 | ROI: -333.93% |
+--------------------+----------------------+------------------------+-----------------------+
| RSI (14): 56.65 | Market Cap: 45.59M | Short Interest: 0.07M | Sales Surprise: - |
+--------------------+----------------------+------------------------+-----------------------+
| ATR (14): 0.54 | Shs Outstand: 11.82M | Beta: - | EPS Surprise: -27.07% |
+--------------------+----------------------+------------------------+-----------------------+
| SMA20: 16.48% | Shs Float: 2.67M | Sales Q/Q: - | P/E: - |
+--------------------+----------------------+------------------------+-----------------------+
| SMA50: 17.85% | Inst Own: 12.72% | Sales past 5Y: 0.00% | Earnings: Feb 26 |
+--------------------+----------------------+------------------------+-----------------------+
| SMA200: 21.18% | Insider Own: 77.42% | Employees: 12 | |
+--------------------+----------------------+------------------------+-----------------------+
| Perf Week: 16.88% | Insider Trans: 0.00% | Debt/Eq: 0.10 | |
+--------------------+----------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -11155516.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.82
Average Volume: 69072.39
30-Day High: 3.96
30-Day Low: 2.61

[Detailed Financials: TTM 2024]
- Total Assets: $5,646,878.0
- Total Liabilities: $2,512,174.0
- Total Equity: $3,134,704.0
- Current Assets: $5,378,307.0
- Current Liabilities: $2,306,229.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.16

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0

[Detailed Financials: FY 2024]
- Total Assets: $5,646,878.0
- Total Liabilities: $2,512,174.0
- Total Equity: $3,134,704.0
- Current Assets: $5,378,307.0
- Current Liabilities: $2,306,229.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.16

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

MDCX_OUT_23 [2025-04-03 14:16:40 -0400] 676 Bytes | 167 tokens | Cum: 4701 tkns (58.76% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

MDCX_IN_25 [2025-04-03 14:16:40 -0400] 126 Bytes | 29 tokens | Cum: 4807 tkns (60.09% of 8k)
==========================================================================

====================================
[2025-04-03 14:16:40] # Analysis Completed
Elapsed Time: 33.31 seconds